Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given… | Phase 2 | terminated | Apr 9, 2014 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT01646125 | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed… | Phase 2 | terminated | Jul 20, 2012 | Novartis Pharmaceuticals | An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended… | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT02431169 | Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease… | — | terminated | Apr 30, 2015 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | Phase 1 / Phase 2 | terminated | Mar 21, 2016 | PrECOG, LLC. | Company discontinued further development of study drug for this indication | Sponsor / business decision |
| NCT02630186 | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in… | Phase 1 / Phase 2 | terminated | Dec 15, 2015 | Clovis Oncology, Inc. | The study terminated before Phase 1 was completed. This study was reprioritized within the… | Other (stated, no rule matched) |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT00714246 | Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With… | Phase 1 | terminated | Jul 14, 2008 | Milton S. Hershey Medical Center | Low accrual | Enrollment / accrual |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma | N/A | terminated | May 28, 2008 | GlaxoSmithKline | Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number of… | Enrollment / accrual |
| NCT03121417 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | Phase 2 | withdrawn | Apr 20, 2017 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02410382 | Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for… | Phase 2 | terminated | Apr 7, 2015 | University of Arizona | IRB suspension, did not resume | Other (stated, no rule matched) |
| NCT02186301 | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With…(EGFR) | Phase 2 / Phase 3 | terminated | Jul 10, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC | Other (stated, no rule matched) |
| NCT02080078 | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | Phase 1 | terminated | Mar 6, 2014 | AHS Cancer Control Alberta | REB decision | Other (stated, no rule matched) |
| NCT00568906 | Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung… | — | terminated | Dec 6, 2007 | Stanford University | not stated | Not stated |
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild… | Phase 3 | terminated | May 17, 2016 | The Netherlands Cancer Institute | accrual to slow, target not achievable | Enrollment / accrual |
| NCT03419559 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in… | Phase 2 | withdrawn | Feb 5, 2018 | Iovance Biotherapeutics, Inc. | The treatment landscape for NSCLC has evolved in the past year. An additional NSCLC arm will be… | Other (stated, no rule matched) |
| NCT00793208 | Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Nov 19, 2008 | Theresa Whiteside, PhD | study closed due to low enrollment | Enrollment / accrual |
| NCT02556593 | IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10… | Phase 2 | terminated | Sep 22, 2015 | Sun Yat-sen University | not stated | Not stated |
| NCT03166254 | Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care… | Phase 1 | withdrawn | May 25, 2017 | Washington University School of Medicine | Lost funding | Funding |
| NCT02542930 | Abscopal Effect for Metastatic Non-small Cell Lung Cancer. | Phase 2 | withdrawn | Sep 7, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT02106559 | Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy | N/A | withdrawn | Apr 8, 2014 | Ohio State University Comprehensive Cancer Center | not stated | Not stated |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 4, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of… | Phase 1 | terminated | Apr 26, 2016 | Boehringer Ingelheim | Terminated- Study halted due to low recruitment. | Enrollment / accrual |
| NCT00784329 | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway… | N/A | withdrawn | Nov 3, 2008 | Lahey Clinic | not stated | Not stated |
| NCT02355431 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With… | Phase 2 | withdrawn | Feb 4, 2015 | Incyte Corporation | Study withdrawn before enrolling first patient | Enrollment / accrual |
| NCT00153842 | A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in… | Phase 1 / Phase 2 | terminated | Sep 12, 2005 | Dartmouth-Hitchcock Medical Center | other trials show no survival benefit of bexarotene with platinum-based chemo | Other (stated, no rule matched) |
| NCT03172988 | Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery | Phase 4 | terminated | Jun 1, 2017 | Peking University First Hospital | Protocol violation occurred frequently during the postoperative period. | Other (stated, no rule matched) |
| NCT02846792 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or… | Phase 1 / Phase 2 | terminated | Jul 27, 2016 | University of Washington | Immunotherapy approved for NSCLC in the first line setting | Other (stated, no rule matched) |
| NCT02483416 | Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance | — | terminated | Jun 26, 2015 | Boehringer Ingelheim | Poor recruitment | Enrollment / accrual |
| NCT00969306 | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients(Chloroquine IV) | Phase 1 | terminated | Sep 1, 2009 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT01210378 | Nitroglycerin in Non-small Cell Lung Cancer(Nitroglycerin) | Phase 2 | terminated | Sep 28, 2010 | Maastricht Radiation Oncology | Accrual stopped | Enrollment / accrual |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for… | Phase 3 | terminated | Apr 6, 2015 | Hoffmann-La Roche | The study was closed due to low patient enrollment and the Sponsor's decision to include patients… | Enrollment / accrual |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With…(PRIMAL) | Phase 1 | terminated | Jan 27, 2015 | Halozyme Therapeutics | Changing standard of care therapy regimen | Other (stated, no rule matched) |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT01207726 | Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer… | Phase 2 | terminated | Sep 23, 2010 | National Cancer Institute (NCI) | Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of… | Enrollment / accrual |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung…(NTS) | — | withdrawn | Sep 7, 2016 | Fondation Hôpital Saint-Joseph | The principal investigator decided to stop the study. | Investigator |
| NCT00769600 | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated… | Phase 2 | terminated | Oct 9, 2008 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual. | Enrollment / accrual |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With…(METAL2) | Phase 3 | terminated | Jun 12, 2014 | Centre Hospitalier Intercommunal Creteil | Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for… | Other (stated, no rule matched) |
| NCT02258607 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic… | Phase 1 | terminated | Oct 7, 2014 | Sierra Oncology LLC - a GSK company | not stated | Not stated |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | Phase 2 / Phase 3 | withdrawn | Nov 17, 2017 | University College, London | drug no longer available | Other (stated, no rule matched) |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Jul 3, 2013 | Pfizer | The study was terminated on June 23, 2015 due to the company's change in prioritization for the… | Safety / toxicity |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 6, 2012 | Eli Lilly and Company | Change in clinical strategy. | Sponsor / business decision |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment… | Phase 3 | withdrawn | Nov 7, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02353741 | Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line…(CERTAIN) | Phase 2 | terminated | Feb 3, 2015 | Xinqiao Hospital of Chongqing | too slow of recruitmentc | Enrollment / accrual |
| NCT02640326 | McMaster Catheterization for Thoracoscopic Surgery Study(UCATh) | N/A | withdrawn | Dec 28, 2015 | McMaster University | Research question no longer useful/feasible due to shifts in standards of care | Other (stated, no rule matched) |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With… | Phase 2 | terminated | Apr 17, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT00924209 | A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA… | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | Phase 2 | terminated | Dec 8, 2017 | Samsung Medical Center | Early detection of the purpose of the study. | Other (stated, no rule matched) |
| NCT03519958 | Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong | — | withdrawn | May 9, 2018 | AstraZeneca | The study direction does not longer aligns the sponsor's strategy | Sponsor / business decision |
| NCT00745732 | Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | Sponsor withdrew support. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 29, 2019source: clinicaltrials